Physician profile
Precious Idogun
NPI 1386271385
$2,053.88
in general payments reported to CMS, 2019-2025
23 companies · $991 in 2025
The $991 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $95.00 · 2024: $967 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.46 |
| Education | $296.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $361.27 | 2024-2025 | Blincyto, Blincyto, Imdelltra (Amg757) |
| Genzyme Corporation | $216.21 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $203.29 | 2025 | |
| Janssen Biotech, INC. | $190.49 | 2024-2025 | Rybrevant, Talvey, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $161.74 | 2024-2025 | Lynparza |
| Glaxosmithkline, LLC. | $145.76 | 2024-2025 | Ojjaara |
| Lilly USA, LLC | $123.20 | 2024-2025 | Verzenio, Jaypirca |
| Sobi, INC | $113.90 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $99.76 | 2024-2025 | Keytruda |
| Genentech USA, INC. | $79.21 | 2024-2025 | Polivy, Venclexta |
| E.R. Squibb & Sons, L.L.C. | $39.06 | 2024-2025 | Opdualag, Krazati |
| Caris Mpi, INC. | $37.29 | 2025 | Mi Cancer Seek |
| Geron Corporation | $36.12 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $32.97 | 2024 | |
| Dendreon Pharmaceuticals LLC | $29.71 | 2024 | Provenge |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $28.71 | 2025 | Datroway |
| Sun Pharmaceutical Industries INC. | $26.20 | 2024 | |
| Beone Medicines USA, INC. | $24.52 | 2025 | Tevimbra |
| Ipsen Biopharmaceuticals, INC | $22.10 | 2025 | Onivyde |
| Astellas Pharma US INC | $21.87 | 2025 | Xtandi |
| Pharmaessentia USA Corporation | $21.71 | 2025 | Besremi |
| Deciphera Pharmaceuticals INC. | $20.60 | 2025 | Qinlock |
| Bayer Healthcare Pharmaceuticals INC. | $18.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Precious Idogun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.